Clarity Pharmaceuticals Ltd (ASX:CU6) Insider Thomas Ramdahl Purchases 400,000 Shares of Stock

Clarity Pharmaceuticals Ltd (ASX:CU6Get Free Report) insider Thomas Ramdahl bought 400,000 shares of the company’s stock in a transaction that occurred on Thursday, March 21st. The shares were acquired at an average cost of A$0.61 ($0.40) per share, with a total value of A$242,000.00 ($159,210.53).

Clarity Pharmaceuticals Price Performance

Clarity Pharmaceuticals Company Profile

(Get Free Report)

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product includes SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2.

Recommended Stories

Receive News & Ratings for Clarity Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clarity Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.